The Preparation and Specificity of Antibody to Thyrotropin Releasing Hormone1

Bassiri, Rahim M.; Utiger, Robert D.

doi:10.1210/endo-90-3-722

Cited by 250 publications

(54 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These indicate that our TRF antiserum can distinguish imino acids with four-, five-, and six-membered rings of the C-terminus moiety. Bassiri and Utiger (1972) suggested that the major determinants of immunological activity and biological active site of TRF might be similar, and our present results which showed a coincidence between biological and immunological activities of LPip3-TRF seem to support their view. Grant et al(1973) reported that the association constants of TRF and TRF analogues to anterior pituitary TRF membrane receptor were proportional to their biological potencies.…”

Section: Discussionsupporting

confidence: 88%

“…The data for crossreactivity of the TRF antiserum produced by us showed that our TRF antiserum was specific to synthetic TRF except for L-Pip3-TRF, compared with the data of Bassiri and Utiger (1972), Visser et al (1974), Mitsuma et al (1974), and Saito et al (1975). Mitsuma et al (1974) did not examine the crossreactivity of L-Pip3-TRF, although they mentioned that of L-Aze3-TRF was 2.5%.…”

Section: Discussionmentioning

confidence: 78%

“…TRF antiserum. TRF was conjugated to bovine serum albumin (BSA; Armour, Fraction V) with bis-diazotized benzidine according to the method of Bassiri and Utiger (1972). This TRF-BSA conjugate was dissolved in 0.15 M NaCl at a concentration of 2 mg/ml, then emulsified with complete Freund's adjuvant, and injected intradermally to rabbits once a week for 3 months.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Immunological and biological characteristics of a new TRF analogue, L-pyroglutamyl-L-histidyl-L-pipecolic acid amide.

1977

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 78%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Immunological and biological characteristics of a new TRF analogue, L-pyroglutamyl-L-histidyl-L-pipecolic acid amide.

1977

View full text Add to dashboard Cite

“…The hypothalami were cultured in groups of three and maintained in a humidified incubator overnight (24 hr) at 370 in an atmosphere of 5% C02/95% air. The use of heat-inactivated fetal calf serum and bacitracin served to prevent enzymatic degradation of TRF (12,13) and represented a major change from published techniques (14,15). At the conclusion of the primary culture a preincubation was carried out for 10 mg/ml (approximately 3-fold greater than the normal concentration in order to facilitate longer cell viability), the addition of bacitracin (2.1 X 10-5 M, pH 7.4) to prevent enzymatic breakdown of TRF, and the use of potassium at twice the normal level in an attempt to maintain the intracellular potassium concentration.…”

mentioning

confidence: 99%

Somatostatin inhibits release of thyrotropin releasing factor from organ cultures of rat hypothalamus.

Hirooka¹,

Hollander²,

Suzuki³

et al. 1978

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Somatostatin in concentrations of 10-6 to 10-8 M inhibited basal release of thyrotropin releasing factor in organ culture of rat hypothalamus. Norepinephrine in doses of 10-4-10-6 M induced release of thyrotropin releasing factor which increased progressively with time and was temperature and dose dependent. This enhanced thyrotropin-releasing-factor release was inhibited by somatostatin at 10-6-10-8 M. The tetradecapeptide somatostatin, which is extensively distributed throughout the central nervous system, gastrointestinal tract, and pancreas (1-3), inhibits release of various hormones including growth hormone (4), thyrotropin (5), glucagon (6) and insulin (4). Somatostatin infusion lowers circulating thyrotropin in man (7), and passive immunization of rats with specific somatostatin antiserum increases basal and thyrotropin releasing factor (TRF)-stimulated thyrotropin secretion (8). These experiments imply an interrelationship between TRF and somatostatin and pituitary thyrotropin secretion. Potential local effects of somatostatin within the hypothalamus itself, either directly on peptide hormone secretion or via an action upon neurotransmitters, are equally likely and have not been critically examined.Studies of the regulation of TRF synthesis and release are complicated by the fact that the hormone is widely distributed throughout the central nervous system so that measurements of the hormone in the peripheral blood, regardless of their accuracy, may not faithfully mirror concentrations of TRF actually delivered to the anterior pituitary (9). Moreover, measurements of hormone levels in the hypophyseal portal circulation require surgical cannulation under anesthesia which entails the administration of anesthetics, many of which affect hypothalamic hormone release (10), and in most instances measurements require prior hypophysectomy as well, to permit sampling of the entire hypothalamic outflow (11). Our own approach has been to utilize short-term organ culture of rat hypothalamus as a model for delineating factors modulating in vitro release of TRF. We have found that somatostatin at 10-6 M-10-8 M inhibits basal release of TRF. Moreover, norepinephrine (NE) in doses of 10-4-10-6 M increases release of TRF, an effect which is not seen in the presence of somatosta- were killed by decapitation at 10-11 a.m. After the brain was exposed by removal of the skull with sterile instruments, it was carefully placed in a sterile plastic petri dish which contained Ca2+, Mg2+-free Hanks' balanced salt solution, bacitracin (2.1 X 10-5 M), and glucose (6 mg/ml). Prior to use the dishes had been "gassed" with 5% C02/95% air. Dissection was performed in a laminar flow hood with sterile instruments at a plane 1 mm lateral to the midline and at a depth of 1 mm. The fragments were obtained from the area between the posterior margin of the optic chiasm and the anterior portion of the mammillary body. Microscopic examination (Fig. 2) demonstrated that the fragments included parts of the paraventricular, dorsomedial, vent...

show abstract

“…The TRH antibody was prepared in rabbits immunized with a TRH-BSA conjugate formed with bis-diazotised benzidine 1 . A 100 μl sample was combined with equal volumes of TRH antisera (1:1000) and 10,000 dpm of [ 125 I]TRH.…”

Section: Biochemistrymentioning

confidence: 99%

Early postnatal administration of 5,7-dihydroxytryptamine: Effects on substance P and thyrotropin-releasing hormone neurons and terminals in rat brain

et al. 1986

View full text Add to dashboard Cite

Substance P, thyrotropin-releasing hormone (TRH) and serotonin are putative neurotransmitters which have been proposed to coexist in some brain neurons Our previous immunocytochemical and biochemical studies have demonstrated that 85-100% of all serotonin neurons are destroyed following neonatal 5,7-dihydroxtryptamine (5,7-DHT) treatment In this study, we have determined the effect of neonatal 5,7-DHT and desipramine (DMI) treatment on the biochemical content and immunocytochemical localization of substance P and TRH throughout the brain Interestingly, we have observed that virtually all substance P-and TRH-immunoreactive cells in the ventral pons-medulla are destroyed by the neurotoxin. However, peptide-containing neurons in other regions were not affected Additionally, we measured the peptide content and found that TRH is significantly decreased in the spinal cord (−50%) and pons-medulla (−20%), but not in other brain regions Substance P content was not significantly altered in any region, even after a greater than 90% reduction of serotonin These data indicate that the co-localized substance P and TRH forms a small proportion of the total peptide in brain Correspondence A Towle,

show abstract

The Preparation and Specificity of Antibody to Thyrotropin Releasing Hormone1

Cited by 250 publications

References 0 publications

Immunological and biological characteristics of a new TRF analogue, L-pyroglutamyl-L-histidyl-L-pipecolic acid amide.

Immunological and biological characteristics of a new TRF analogue, L-pyroglutamyl-L-histidyl-L-pipecolic acid amide.

Somatostatin inhibits release of thyrotropin releasing factor from organ cultures of rat hypothalamus.

Early postnatal administration of 5,7-dihydroxytryptamine: Effects on substance P and thyrotropin-releasing hormone neurons and terminals in rat brain

Contact Info

Product

Resources

About